文献速递流行病学与生物统计组学、生物样本库与精准医学

遗传决定的血清尿酸水平与英国生物银行队列中心血管及其他疾病:一项全表型孟德尔随机化研究

Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study.
PubMed 文献 · PLoS Med · 2019-10-18

在英国生物银行339,256名无亲缘关系的英国白人(54%女性,招募时年龄40-69岁,平均56.87岁,标准差7.99)中,采用全表型关联研究(PheWAS)和树结构表型贝叶斯分析(TreeWAS)及孟德尔随机化(MR)分析,发现遗传决定的血清尿酸水平与痛风、高血压、心脏病及血脂水平相关,并提示遗传多效性存在。

要点

  • PheWAS分析识别出13个独立 phecode,涉及4个疾病组和9个疾病结局与遗传决定的血清尿酸水平相关。
  • TreeWAS分析识别出更多心脑血管疾病亚表型,如心绞痛、心力衰竭、脑梗死。
  • MR分析成功重复了与痛风、高血压、心脏病和血脂水平的关联,但提示存在遗传多效性。

核心结论

  • 本研究发现高血清尿酸水平与不同类型心脏事件风险增加相关。
  • 遗传多效性的发现表明存在共同的上游病理因素影响尿酸和代谢特征,这可能为开发针对共同介导者的药物提供新机会和挑战,该药物将有益于痛风治疗和心血管合并症的预防。

研究设计与样本

  • 研究在英国生物银行339,256名无亲缘关系的英国白人(54%女性)中进行,招募时年龄40-69岁(平均56.87岁,标准差7.99),招募时间为2006年至2010年。
  • 采用全表型关联研究(PheWAS)和树结构表型贝叶斯分析(TreeWAS)检查与遗传决定的血清尿酸水平相关的疾病结局。
  • 采用孟德尔随机化(MR)分析,使用多个全基因组关联研究(GWAS)联盟数据重复显著发现。
  • 进行敏感性分析以检查所用尿酸遗传变异对代谢特征的潜在多效性效应。

主要发现

  • PheWAS分析检查了1,431个疾病结局,识别出13个独立phecode,代表4个疾病组(炎性多关节炎、高血压病、循环系统疾病和代谢紊乱)和9个疾病结局(痛风、痛风性关节炎、化脓性关节炎、原发性高血压、冠状动脉粥样硬化、缺血性心脏病、慢性缺血性心脏病、心肌梗死和高胆固醇血症),在多重检验校正后(p < 3.35 × 10-4)与遗传决定的血清尿酸水平相关。
  • TreeWAS分析检查了10,750个ICD-10诊断术语,识别出更多心脑血管疾病亚表型(例如心绞痛、心力衰竭、脑梗死)。
  • MR分析成功重复了与痛风、高血压、心脏病和血脂水平的关联,但表明存在遗传多效性。
  • 敏感性分析支持以下推断:遗传变异对尿酸和代谢特征的多效性效应导致了与心血管疾病的观察性关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究的主要局限性涉及所考虑遗传变异的多效性效应可能带来的偏倚,以及不需要住院的轻症病例可能被错误分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of urate in cardiovascular diseases (CVDs) has been extensively investigated in observational studies; however, the extent of any causal effect remains unclear, making it difficult to evaluate its clinical relevance. METHODS AND FINDINGS: A phenome-wide association study (PheWAS) together with a Bayesian analysis of tree-structured phenotypic model (TreeWAS) was performed to examine disease outcomes related to genetically determined serum urate levels in 339,256 unrelated White British individuals (54% female) in the UK Biobank who were aged 40-69 years (mean age, 56.87; SD, 7.99) when recruited from 2006 to 2010. Mendelian randomization (MR) analyses were performed to replicate significant findings using various genome-wide association study (GWAS) consortia data. Sensitivity analyses were conducted to examine possible pleiotropic effects on metabolic traits of the genetic variants used as instruments for urate. PheWAS analysis, examining the association with 1,431 disease outcomes, identified 13 distinct phecodes representing 4 disease groups (inflammatory polyarthropathies, hypertensive disease, circulatory disease, and metabolic disorders) and 9 disease outcomes (gout, gouty arthropathy, pyogenic arthritis, essential hypertension, coronary atherosclerosis, ischemic heart disease, chronic ischemic heart disease, myocardial infarction, and hypercholesterolemia) that were associated with genetically determined serum urate levels after multiple testing correction (p < 3.35 × 10-4). TreeWAS analysis, examining 10,750 ICD-10 diagnostic terms, identified more sub-phenotypes of cardiovascular and cerebrovascular diseases (e.g., angina pectoris, heart failure, cerebral infarction). MR analysis successfully replicated the association with gout, hypertension, heart diseases, and blood lipid levels but indicated the existence of genetic pleiotropy. Sensitivity analyses support an inference that pleiotropic effects of genetic variants on urate and metabolic traits contribute to the observational associations with CVDs. The main limitations of this study relate to possible bias from pleiotropic effects of the considered genetic variants and possible misclassification of cases for mild disease that did not require hospitalization. CONCLUSION: In this study, high serum urate levels were found to be associated with increased risk of different types of cardiac events. The finding of genetic pleiotropy indicates the existence of common upstream pathological elements influencing both urate and metabolic traits, and this may suggest new opportunities and challenges for developing drugs targeting a common mediator that would be beneficial for both the treatment of gout and the prevention of cardiovascular comorbidities.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Li X, Meng X, He Y, et al. Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study. PLoS Med. 2019. PMID: 31626644. doi:10.1371/journal.pmed.1002937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。